Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
Crossref DOI link: https://doi.org/10.1007/s00280-014-2615-5
Published Online: 2014-11-25
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tolcher, Anthony W.
Patnaik, Amita
Papadopoulos, Kyriakos P.
Rasco, Drew W.
Becerra, Carlos R.
Allred, Alicia J.
Orford, Keith
Aktan, Gursel
Ferron-Brady, Geraldine
Ibrahim, Nageatte
Gauvin, Jennifer
Motwani, Monica
Cornfeld, Mark
Text and Data Mining valid from 2014-11-25